355 related articles for article (PubMed ID: 26571110)
1. Establishing the Evidence Bar for Molecular Diagnostics in Personalised Cancer Care.
Schneider D; Bianchini G; Horgan D; Michiels S; Witjes W; Hills R; Plun-Favreau J; Brand A; Lawler M;
Public Health Genomics; 2015; 18(6):349-58. PubMed ID: 26571110
[TBL] [Abstract][Full Text] [Related]
2. Budget impact and cost-effectiveness: can we afford precision medicine in oncology?
Doble B
Scand J Clin Lab Invest Suppl; 2016; 245():S6-S11. PubMed ID: 27426412
[TBL] [Abstract][Full Text] [Related]
3. The evolving potential of companion diagnostics.
Khoury JD
Scand J Clin Lab Invest Suppl; 2016; 245():S22-5. PubMed ID: 27433788
[TBL] [Abstract][Full Text] [Related]
4. Challenges in the clinical implementation of precision medicine companion diagnostics.
Keeling P; Clark J; Finucane S
Expert Rev Mol Diagn; 2020 Jun; 20(6):593-599. PubMed ID: 32336167
[TBL] [Abstract][Full Text] [Related]
5. Next generation sequencing in cancer: opportunities and challenges for precision cancer medicine.
Paolillo C; Londin E; Fortina P
Scand J Clin Lab Invest Suppl; 2016; 245():S84-91. PubMed ID: 27542004
[TBL] [Abstract][Full Text] [Related]
6. Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients.
van Waalwijk van Doorn-Khosrovani SB; Pisters-van Roy A; van Saase L; van der Graaff M; Gijzen J; Sleijfer S; Hoes LR; van Berge Henegouwen JM; van der Wijngaart H; van der Velden DL; van Werkhoven E; Retel VP; van Harten WH; Huitema ADR; Timmers L; Gelderblom H; Verheul HMW; Voest EE
Ann Oncol; 2019 May; 30(5):663-665. PubMed ID: 31038154
[No Abstract] [Full Text] [Related]
7. The pathway to clinical use of a cancer biomarker.
Henry NL
Scand J Clin Lab Invest Suppl; 2016; 245():S17-21. PubMed ID: 27410238
[TBL] [Abstract][Full Text] [Related]
8. Precision medicine: what's all the fuss about?
Barker R
Scand J Clin Lab Invest Suppl; 2016; 245():S2-5. PubMed ID: 27542001
[TBL] [Abstract][Full Text] [Related]
9. Precision Medicine Requires Precision Laboratories.
Rajeevan MS; Li T; Unger ER
J Mol Diagn; 2017 Mar; 19(2):226-229. PubMed ID: 28130021
[TBL] [Abstract][Full Text] [Related]
10. CM-Path Molecular Diagnostics Forum-consensus statement on the development and implementation of molecular diagnostic tests in the United Kingdom.
Macklin PS; Pillay N; Lee JL; Pitman H; Scott S; Wang J; Craig C; Jones JL; Oien KA; Colling R; Coupland SE; Verrill C;
Br J Cancer; 2019 Oct; 121(9):738-743. PubMed ID: 31575975
[TBL] [Abstract][Full Text] [Related]
11. Clinical relevance of molecular diagnostics in gastrointestinal (GI) cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 17th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona.
Baraniskin A; Van Laethem JL; Wyrwicz L; Guller U; Wasan HS; Matysiak-Budnik T; Gruenberger T; Ducreux M; Carneiro F; Van Cutsem E; Seufferlein T; Schmiegel W
Eur J Cancer; 2017 Nov; 86():305-317. PubMed ID: 29065378
[TBL] [Abstract][Full Text] [Related]
12. Companion and complementary diagnostics: an important treatment decision tool in precision medicine.
Jørgensen JT
Expert Rev Mol Diagn; 2020 Jun; 20(6):557-559. PubMed ID: 32342707
[No Abstract] [Full Text] [Related]
13. Molecular predictive testing in precision oncology: The Italian experience.
Vigliar E; Iaccarino A; Sciortino M; De Luca C; Malapelle U; Bellevicine C; Troncone G
Cancer Cytopathol; 2020 Sep; 128(9):622-628. PubMed ID: 32885914
[TBL] [Abstract][Full Text] [Related]
14. Study protocol: Whole genome sequencing Implementation in standard Diagnostics for Every cancer patient (WIDE).
Samsom KG; Bosch LJW; Schipper LJ; Roepman P; de Bruijn E; Hoes LR; Riethorst I; Schoenmaker L; van der Kolk LE; Retèl VP; Frederix GWJ; Buffart TE; van der Hoeven JJM; Voest EE; Cuppen E; Monkhorst K; Meijer GA
BMC Med Genomics; 2020 Nov; 13(1):169. PubMed ID: 33167975
[TBL] [Abstract][Full Text] [Related]
15. Drug sensitivity testing platforms for gastric cancer diagnostics.
Lau V; Wong AL; Ng C; Mok Y; Lakshmanan M; Yan B
J Clin Pathol; 2016 Feb; 69(2):93-6. PubMed ID: 26567318
[TBL] [Abstract][Full Text] [Related]
16. Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment.
Schmidt KT; Chau CH; Price DK; Figg WD
J Clin Pharmacol; 2016 Dec; 56(12):1484-1499. PubMed ID: 27197880
[TBL] [Abstract][Full Text] [Related]
17. How Imaging Biomarkers Can Inform Clinical Trials and Clinical Practice in the Era of Targeted Cancer Therapy.
Farwell MD; Clark AS; Mankoff DA
JAMA Oncol; 2015 Jul; 1(4):421-2. PubMed ID: 26181243
[No Abstract] [Full Text] [Related]
18. Protein array-based companion diagnostics in precision medicine.
Poulsen TBG; Karamehmedovic A; Aboo C; Jørgensen MM; Yu X; Fang X; Blackburn JM; Nielsen CH; Kragstrup TW; Stensballe A
Expert Rev Mol Diagn; 2020 Dec; 20(12):1183-1198. PubMed ID: 33315478
[TBL] [Abstract][Full Text] [Related]
19. Making Molecular Imaging a Clinical Tool for Precision Oncology: A Review.
Mankoff DA; Farwell MD; Clark AS; Pryma DA
JAMA Oncol; 2017 May; 3(5):695-701. PubMed ID: 28033451
[TBL] [Abstract][Full Text] [Related]
20. New Institute of Medicine Report on Molecular Biomarkers.
Terry SF
Genet Test Mol Biomarkers; 2016 May; 20(5):221-2. PubMed ID: 27077401
[No Abstract] [Full Text] [Related]
[Next] [New Search]
